All In Biotech

Drug Trial Radar · NCT07684937

HL-300 Ointment in Healthy Volunteers

A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HL-300 Ointment After Single and Multiple Doses in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Jun 14, 2024

Primary completion

Nov 25, 2024

Study completion Nov 25, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of HL-300 ointment following single and multiple topical administrations in healthy Chinese adult volunteers.

Conditions

  • Atopic Dermatitis

Interventions

  • HL-300Drug

    Number of Healthy Volunteers:4 (Treatment group: 3, Placebo\*: 1)

  • HL-300Drug

    Number of Healthy Volunteers:8 (Treatment group: 6, Placebo: 2);Dosing Days:Day 1;

  • HL-300Drug

    Number of Healthy Volunteers:12 (Treatment group: 10, Placebo: 2);Dosing Days:Day 1

  • HL-300Drug

    Number of Healthy Volunteers:12 (Treatment group: 10, Placebo: 2);Dosing Days:Day 1-Day 7, BID;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single dose: Day3 Day 8;Multiple dose: Day7 Day14
  2. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single dose:Day3 Day 8;Multiple dose: Day7 Day14
  3. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single dose:Day3, Day 8;Multiple dose: Day3, Day5, Day7, Day9, Day11, Day14
  4. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single dose:Day3 Day 8;Multiple dose: Day7 Day14
  5. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single-dose: Pre-dose Day1,post-dose Day1-12hour , Day2, Day3, Day8. Multiple-dose: Pre-dose Day1, Day4, Day7,post-dose Day1-12hour , Day7-12hour, Day10, Day14.
  6. To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single dose: Day 8; Multiple dose: Day7, Day14

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.